Paul Richardson, MD

• Multiple Myeloma 

Paul G. Richardson is the Director of Clinical Research and the Clinical Program Leader of the Jerome
Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, as well as the RJ Corman Professor of
Medicine at Harvard Medical Schoool. After certification in Internal Medicine, Hematology, and Medical
Oncology, as well as working in Cancer Pharmacology from 1994 onwards at Dana-Farber Cancer
Institute (DFCI), he joined the Jerome Lipper Myeloma Center in 1999 and became clinical director in
2001 staying in this role until taking on his current roles in 2013. He was a co-recipient of the prestigious
Warren Alpert Foundation Prize in recognition of the successful therapeutic targeting of the ubiquitin-
proteasome pathway in 2012. He was also a co-recipient of the Accelerator Award for contributions to
clinical research and patient enrollment in MMRC studies, as well as for the Research Center of the Year
Award in 2009, followed by the second award for Center of the Year in 2017.
He was ranked by Thomson Reuters Science Watch amongst the top 19 investigators at DFCI for the
most highly cited research in 2016 and in 2022. He was the co-recipient of the ASH Ernest Beutler Prize
for clinical science and translational research in the development of proteasome inhibition as an
effective treatment strategy for multiple myeloma in 2015; the COMY Award for MM research (Paris,
France) in 2016, and the prestigious IMF Robert A. Kyle Lifetime Achievement Award in 2017, and the
Morse Research Award in 2019. He has authored over 810 publications with a total citation of 102,381
and an h-index of 164 (Scopus).